Skip to main content
Clinical Trials/ISRCTN40815027
ISRCTN40815027
Active, not recruiting
未知

Verification of urinary Xpert bladder cancer detection test in patients with haematuria

niversity of Dundee0 sites600 target enrollmentDecember 23, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Suspected bladder cancer
Sponsor
niversity of Dundee
Enrollment
600
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 23, 2020
End Date
August 31, 2023
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of Dundee

Eligibility Criteria

Inclusion Criteria

  • 1\. Adults over the age of 18
  • 2\. Presenting with visible and non\-visible haematuria within 12 weeks of the consent visit
  • 3\. Scheduled for a standard of care cystoscopy
  • 4\. Agrees to provide voided urine for trial purposes
  • 5\. Able to consent

Exclusion Criteria

  • 1\. Previous diagnosis of bladder cancer
  • 2\. Previous history of kidney stone
  • 3\. Indwelling urethral catheter
  • 4\. Ongoing urinary tract infection
  • 5\. Not able to consent

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-001819-30-DESanochemia Pharmazeutika AG220
Active, not recruiting
Not Applicable
Detection of bladder cancer using a fluorescent dye (PVP-Hypericin)Suspected non-muscle invasive (superficial) bladder cancerMedDRA version: 17.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2011-001819-30-ATSanochemia Pharmazeutika AG220
Completed
Phase 2
Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy(Hypericin PDD)C67Malignant neoplasm of bladder
DRKS00003324Sanochemia Pharmazeutika AG227
Not yet recruiting
Not Applicable
Diagnosis of bladder cancer using probe-based confocal laser endomicroscopyBladder Cancer
JPRN-UMIN000021067Depatment of Urology, Kyoto Prefectural University of Medicine50
Completed
Not Applicable
Xpert bladder cancer monitor test for bladder cancer surveillanceon-muscle invasive bladder cancerCancerNon-muscle invasive bladder cancer
ISRCTN37210907Medical University Innsbruck150